Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · IEX Real-Time Price · USD
1.235
+0.075 (6.47%)
At close: Jul 23, 2024, 3:59 PM
1.240
+0.005 (0.40%)
After-hours: Jul 23, 2024, 4:00 PM EDT

Chemomab Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018 - 2016
Selling, General & Admin
5.857.0811.566.031.296.25
Upgrade
Research & Development
14.6118.3816.986.334.6813.3
Upgrade
Other Operating Expenses
000003.35
Upgrade
Operating Expenses
20.4625.4628.5312.375.9722.9
Upgrade
Operating Income
-20.46-25.46-28.53-12.37-5.97-22.9
Upgrade
Interest Expense / Income
000004.23
Upgrade
Other Expense / Income
-1.1-1.24-0.350.11-0.02-
Upgrade
Pretax Income
-19.36-24.22-28.18-12.48-5.95-27.12
Upgrade
Income Tax
-0.020-0.53000
Upgrade
Net Income
-19.34-24.22-27.65-12.48-5.95-27.12
Upgrade
Shares Outstanding (Basic)
2842352282071379
Upgrade
Shares Outstanding (Diluted)
2842352282071379
Upgrade
Shares Change
28.58%3.26%9.70%51.71%1488.06%172.65%
Upgrade
EPS (Basic)
-1.56-2.06-2.42-1.20-0.88-63.20
Upgrade
EPS (Diluted)
-1.56-2.06-2.42-1.20-0.88-63.20
Upgrade
Free Cash Flow
--23.61-20.44-11.61-5.28-16.55
Upgrade
Free Cash Flow Per Share
--2.01-1.80-1.12-0.77-38.44
Upgrade
EBITDA
--24.15-28.12-12.44-5.93-22.62
Upgrade
Depreciation & Amortization
-0.070.060.030.020.28
Upgrade
EBIT
-19.36-24.22-28.18-12.48-5.95-22.9
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).